Pfizer Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 23, 2026
(Exact name of registrant as specified in its charter)
| (State or other | (Commission File | (I.R.S. Employer | ||||||
| jurisdiction of | Number) | Identification No.) | ||||||
| incorporation) | ||||||||
| (Zip Code) | ||||||||
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(212 ) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 Submission of Matters to a Vote of Security Holders | ||||||||||||||||||||
| (a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 23, 2026. | ||||||||||||||||||||
| (b) Shareholders voted on the matters set forth below. | ||||||||||||||||||||
| 1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 12, 2026 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes: | ||||||||||||||||||||
Nominee | Votes For | Votes Against | Abstentions | Broker non-vote | ||||||||||||||||
| Ronald E. Blaylock | 3,442,653,662 | 102,600,748 | 11,374,500 | 941,392,137 | ||||||||||||||||
| Albert Bourla | 3,261,211,737 | 272,132,573 | 23,284,563 | 941,392,137 | ||||||||||||||||
| Mortimer J. Buckley | 3,403,974,675 | 141,036,932 | 11,617,303 | 941,392,137 | ||||||||||||||||
| Susan Desmond-Hellmann | 3,401,932,807 | 141,056,147 | 13,639,956 | 941,392,137 | ||||||||||||||||
| Joseph J. Echevarria | 2,929,511,380 | 612,413,502 | 14,702,274 | 941,392,137 | ||||||||||||||||
| Scott Gottlieb | 3,415,886,776 | 130,394,185 | 10,343,738 | 941,392,137 | ||||||||||||||||
| Dan R. Littman | 3,383,769,589 | 161,740,872 | 11,118,449 | 941,392,137 | ||||||||||||||||
| Shantanu Narayen | 3,313,318,763 | 231,613,932 | 11,695,915 | 941,392,137 | ||||||||||||||||
| Suzanne Nora Johnson | 3,272,936,863 | 273,506,151 | 10,185,896 | 941,392,137 | ||||||||||||||||
| James Quincey | 3,453,778,741 | 91,549,236 | 11,300,933 | 941,392,137 | ||||||||||||||||
| James C. Smith | 3,284,035,682 | 261,217,699 | 11,375,529 | 941,392,137 | ||||||||||||||||
| Cyrus Taraporevala | 3,468,177,423 | 76,665,721 | 11,785,766 | 941,392,137 | ||||||||||||||||
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was approved based upon the following votes: | |||||||||||
Votes for approval | 4,160,827,231 | ||||||||||
Votes against | 321,979,096 | ||||||||||
Abstentions | 15,214,720 | ||||||||||
Broker non-votes | n/a | ||||||||||
3. The proposal to approve the Pfizer Inc. 2019 Stock Plan, as amended April 2026 was approved based upon the following votes: | |||||||||||
Votes for approval | 3,227,692,578 | ||||||||||
Votes against | 305,428,376 | ||||||||||
Abstentions | 23,507,956 | ||||||||||
Broker non-votes | 941,392,137 | ||||||||||
4. The proposal to approve, on an advisory basis, the 2026 compensation of the Company's Named Executive Officers was approved based upon the following votes: | |||||||||||
Votes for approval | 3,099,249,442 | ||||||||||
Votes against | 423,935,881 | ||||||||||
Abstentions | 33,443,287 | ||||||||||
Broker non-votes | 941,392,137 | ||||||||||
5. The shareholder proposal to Adopt Adopt An Independent Chair Policy was not approved based upon the following votes: | |||||||||||
Votes for approval | 1,015,206,372 | ||||||||||
Votes against | 2,509,042,021 | ||||||||||
Abstentions | 32,354,566 | ||||||||||
Broker non-votes | 941,392,137 | ||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PFIZER INC. | ||||||||
| Dated: April 27, 2026 | By: | /s/ Margaret M. Madden | ||||||
| Margaret M. Madden | ||||||||
| Senior Vice President and Corporate Secretary | ||||||||
| Chief Governance Counsel | ||||||||